Putting Lupus in permanent remission

November 11, 2013

Northwestern Medicine scientists have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease.

This is a positive step toward one day developing a vaccine-like therapy that could keep Lupus in remission in the without the use of .

The study was published online in Clinical Immunology, the journal of the Federation of Clinical Immunology Societies.

Lupus is a chronic, autoimmune disease that causes the body to create autoantibodies that attack and destroy healthy tissue and cause inflammation, pain and damage in various vital organs of the body. According to the Lupus Foundation of America, it is believed that 5 million people throughout the world have a form of .

In past studies, Northwestern scientists showed that a nontoxic therapy (which uses —small bits of protein—to generate special regulatory T cells) blocks lupus in mice that are prone to the disease.

For this new study, 30 (10 active and 20 in remission) and 15 healthy patients were enrolled and their were cultured with low doses of the special peptides.

"We found that the peptides could not only generate regulatory T cells, but also that they block and reduce autoantibody production to almost baseline levels in the blood cultures from people with active Lupus," said Syamal Datta, M.D., senior author of the study. "This approach shows that the peptides have the potential to work like a vaccine in the human body, to boost the regulatory immune system of those with Lupus, fight autoimmune antibodies and keep the disease in remission."

Datta is a professor of medicine-rheumatology and microbiology-immunology at Northwestern University Feinberg School of Medicine.

Steroids and Cytoxan are the most common therapies used to help treat people with lupus and even at very low doses the side effects of the drugs are toxic. Much like chemotherapy, lupus drugs can compromise fertility and weaken the immune system, making it difficult for patients to have children and leaving their bodies susceptible to infections. Also, such toxic drugs cannot be given indefinitely.

"This nontoxic therapy works like a vaccine in that the peptides are recognized by the bodies of almost every individual we have seen," Datta said. "It can be given to both subjects with and without lupus and boost their regulatory response with no side effects. We don't have to design something specifically for an unusual person. It works in everybody."

This study relates to Datta's more than 27 years of research in the lupus field focused on the cloning of the T cells that drive lupus autoimmunity. Datta's team identified the peptides used in this study in 1996, and Northwestern University holds the intellectual rights to these patented discoveries but has published the sequences of the peptides for open access to everyone.

"It is our hope that the next step is a phase one clinical trial in humans to show the efficacy of the peptide therapy in patients with lupus," Datta said. "The key is to find an industry partner that has experience in these kind of therapies so that we can move forward."

Explore further: ACR: Collaboration may up Facebook awareness of lupus

More information: www.sciencedirect.com/science/ … ii/S1521661613002210

Related Stories

ACR: Collaboration may up Facebook awareness of lupus

October 31, 2013
(HealthDay)—Partnering with a lupus foundation is associated with increased patient awareness and participation in Facebook chats about lupus and related health issues, according to a study presented at the annual meeting ...

Headaches in lupus patients not linked to disease activity study says

October 28, 2013
Headache is common among patients with system lupus erythematosus according to new research published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR). The study found that 18% of lupus patients ...

Researchers identify gene variants that may cause kidney problems in lupus patients

August 22, 2013
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). ...

Chronic exposure to staph bacteria may be risk factor for lupus, study finds

August 8, 2012
Chronic exposure to even small amounts of staph bacteria could be a risk factor for the chronic inflammatory disease lupus, Mayo Clinic research shows. Staph, short for Staphylococcus aureus, is a germ commonly found on the ...

Moms with lupus more likely to have children with autism, study suggests

October 28, 2013
(HealthDay)—Women with lupus are twice as likely to have a child with autism compared to mothers without the autoimmune disease, new, preliminary research finds.

Research: Lupus drugs carry no significant cancer risk for patients

January 24, 2013
People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer risk according to new research led by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC). ...

Recommended for you

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

Study finds molecular explanation for struggles of obese asthmatics

July 17, 2017
A large, bouquet-shaped molecule called surfactant protein A, or SP-A, may explain why obese asthma patients have harder-to-treat symptoms than their lean and overweight counterparts, according to a new study led by scientists ...

Team identifies potential cause for lupus

July 14, 2017
Leading rheumatologist and Feinstein Institute for Medical Research Professor Betty Diamond, MD, may have identified a protein as a cause for the adverse reaction of the immune system in patients suffering from lupus. A better ...

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.